Cargando…

Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain

OBJECTIVES: This study estimated the cost of prophylaxis with activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa) in surgical patients with haemophilia A and inhibitors in Spain. METHODS: A decision‐analytic model was developed to estimate the cost to the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mareque, María, Mingot‐Castellano, María Eva, López‐Fernández, María Fernanda, Álvarez‐Román, María Teresa, Oyagüez, Itziar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383573/ https://www.ncbi.nlm.nih.gov/pubmed/32220097 http://dx.doi.org/10.1111/ejh.13414

Ejemplares similares

BAY 81‐8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
por: Santoro, Cristina, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
por: Mareque, Maria, et al.
Publicado: (2021)

Acquired Haemophilia A: A Review of What We Know
por: Mingot-Castellano, María Eva, et al.
Publicado: (2022)

Comparative cost analysis of cervical cancer screening programme based on molecular detection of HPV in Spain
por: Ibáñez, R., et al.
Publicado: (2021)

Concomitant use of bypassing agents with emicizumab for people with haemophilia A and inhibitors undergoing surgery
por: Jiménez‐Yuste, Victor, et al.
Publicado: (2021)

Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis
por: Gros, Blanca, et al.
Publicado: (2015)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

Haemophilia A: Pharmacoeconomic Review of Prophylaxis Treatment versus On-Demand
por: Unim, Brigid, et al.
Publicado: (2015)

Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain
por: Alsina, Laia, et al.
Publicado: (2021)

Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain
por: Rodríguez González-Moro, Jose Miguel, et al.
Publicado: (2015)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
por: Cruz, Maria Sol, et al.
Publicado: (2021)

S301: CONSUMPTION OF FACTOR CONCENTRATES AND BYPASSING AGENTS FOR MANAGEMENT OF BREAKTHROUGH BLEEDS WITH FITUSIRAN PROPHYLAXIS IN PEOPLE WITH HAEMOPHILIA A OR B: ANALYSIS OF ATLAS-PPX
por: Kenet, Gili, et al.
Publicado: (2023)

Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
por: Estrada, Vicente, et al.
Publicado: (2022)

Comparison of Bypassing Agents in Bleeding Reduction in Treatment of Bleeding Episodes in Patients With Haemophilia and Inhibitors
por: Golestani, Mina, et al.
Publicado: (2014)

Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain
por: Sanchez-Luna, M., et al.
Publicado: (2017)

Efficacy and safety in patients with haemophilia A switching to octocog alfa (BAY 81–8973): Final results of the global real‐world study, TAURUS
por: Santoro, Cristina, et al.
Publicado: (2022)

Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain
por: Navarro, F., et al.
Publicado: (2020)

Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain
por: Mingot-Castellano, María-Eva, et al.
Publicado: (2017)

Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention
por: Mokhtar, Fadzlin Mohd, et al.
Publicado: (2021)

Target joint resolution in patients with haemophilia A receiving long‐term prophylaxis with BAY 94‐9027
por: Reding, Mark T., et al.
Publicado: (2020)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Epidemiology & social costs of haemophilia in India
por: Kar, Anita, et al.
Publicado: (2014)

Costs of the management of hemophilia A with inhibitors in Spain
por: Bonanad, Santiago, et al.
Publicado: (2021)

Use of Floseal(®), a human gelatine-thrombin matrix sealant, in surgery: a systematic review
por: Echave, María, et al.
Publicado: (2014)

Prophylaxis use of clotting factor replacement products in people with non‐severe haemophilia: A review of the literature
por: Iorio, Alfonso, et al.
Publicado: (2022)

A new paradigm for personalized prophylaxis for patients with severe haemophilia A
por: Delavenne, Xavier, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia B
por: Mahlangu, Johnny, et al.
Publicado: (2021)

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
por: Calleja, Miguel Angel, et al.
Publicado: (2023)

The cost of severe haemophilia in Europe: the CHESS study
por: O’Hara, Jamie, et al.
Publicado: (2017)

Cost‐effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK
por: Kragh, Nana, et al.
Publicado: (2022)

Issues in pediatric haemophilia care
por: Giordano, Paola, et al.
Publicado: (2013)

Patient Preferences for Pharmacological Diabetes Treatment Among People with Diabetes in Spain: A Discrete Choice Experiment
por: Gómez-Peralta, Fernando, et al.
Publicado: (2021)

S303: A PHASE 3 STUDY (ATLAS-PPX) TO EVALUATE EFFICACY AND SAFETY OF FITUSIRAN IN PEOPLE WITH HAEMOPHILIA A OR B WHO HAVE SWITCHED FROM PRIOR CLOTTING FACTOR CONCENTRATE OR BYPASSING AGENT PROPHYLAXIS
por: Kenet, Gili, et al.
Publicado: (2023)

Hip Replacement Surgery in 14-Year-Old Girl with Factor V Deficiency: Haemostatic Treatment and Thromboprophylaxis
por: Mingot-Castellano, María Eva, et al.
Publicado: (2016)

Acquired Haemophilia A: An Intriguing Disease
por: Mazzucconi, Maria Gabriella, et al.
Publicado: (2020)

Hæmophilia
Publicado: (1905)

Hæmophilia
por: Ruggles, S. D.
Publicado: (1902)

Hæmophilia
por: Porter, Charles A.
Publicado: (1900)

Adherence to Prophylaxis in Adolescents and Young Adults with Severe Haemophilia: A Quantitative Study with Patients
por: van Os, Sandra B., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1madiaudhkfvqiqrln9f8cgipk